This list details many of the research publications and presentations by Institute members during the past financial year. The list is intended to illustrate the extensive range of research conducted by our dermatologists, registrars and research fellows.
2022/2023
Allen, N. C., Martin, A. J., Snaidr, V. A., Eggins, R., Chong, A. H., Fernandéz-Peñas, P., Gin, D., Sidhu, S., Paddon, V. L., Banney, L. A., Lim, A., Upjohn, E., Schaider, H., Ganhewa, A. D., Nguyen, J., McKenzie, C. A., Prakash, S., McLean, C., Lochhead, A., … Damian, D. L. (2023). Nicotinamide for skin-cancer chemoprevention in transplant recipients. New England Journal of Medicine, 388(9), 804–812. https://doi.org/10.1056/nejmoa2203086
Allen, N. C., Martin, A. J., Snaidr, V. A., Eggins, R., Chong, A. H., Fernandéz-Peñas, P., Gin, D., Sidhu, S., Paddon, V. L., Banney, L. A., Lim, A., Upjohn, E., Schaider, H., Ganhewa, A. D., Nguyen, J., McKenzie, C. A., Prakash, S., McLean, C., Lochhead, A., … Damian, D. L. (2023). Nicotinamide for skin-cancer chemoprevention in transplant recipients. New England Journal of Medicine, 388(9), 804–812. https://doi.org/10.1056/nejmoa2203086
2021/2022
Chong, A. H. , Allnutt, K. J., Vogrin, S., Li, J., Goh, M. S., Brennand, S., Davenport, R. (2022). A long‐term cohort study of acitretin for prevention of keratinocyte carcinoma in solid organ transplant recipients. Australasian Journal of Dermatology, 63(2). https://doi.org/10.1111/ajd.13821
Chong, A. H., Mumford, B. P. (2022). A rash of poor cooking. Australian Journal of General Practice, 51(3), 143–144. https://doi.org/10.31128/ajgp-03-21-5901
Chong, A. H., Massey, P. R., Schmults, C. D., Li, S. J., Arron, S. T., Asgari, M. M., Bouwes Bavinck, J. N., Billingsley, E., Blalock, T. W., Blasdale, K., Carroll, B. T., Carucci, J. A., Christensen, S. R., Chung, C. L., DeSimone, J. A., Ducroux, E., Escutia-Muñoz, B., Ferrándiz-Pulido, C., Fox, M. C., … Jambusaria-Pahlajani, A. (2021). Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients. JAMA Dermatology, 157(10), 1219. https://doi.org/10.1001/jamadermatol.2021.3180
Chong, A., Mumford, B. P., Ryan, A., & Lasocki, A. (2022). Follicular mucinosis with novel dermoscopic finding: The toothpaste sign. Clinical and Experimental Dermatology, 47(5), 969–970. https://doi.org/10.1111/ced.15083
Sun, Q., McMahon, D. E., Ugwu-Dike, P. O., Sun, Q., Tang, K., Zhang, H., Suchonwanit, P., Oh, C. C., Chong, A. H., Willems, A., Galván, C., Dodiuk-Gad, R. P., Fantini, F., Recalcati, S., Avancini, J., Miyamoto, D., Sanches, J. A., Raboobee, N., Bravo, F., & Freeman, E. E. (2021). How coronavirus disease 2019 changed dermatology practice in 1 year around the world. Dermatologic Clinics, 39(4), 639–651. https://doi.org/10.1016/j.det.2021.05.014
Willems, A. and Chong, A., 2022, May. The rise and rise of FOAMeD in dermatology education-A review. In AUSTRALASIAN JOURNAL OF DERMATOLOGY (Vol. 63, pp. 58-58).
Willems, A. and Chong, A., 2022, May. Australian General Practitioners’ continuing professional development in dermatological conditions: A Review. In AUSTRALASIAN JOURNAL OF DERMATOLOGY (Vol. 63, pp. 104-104)
Willems, A., Chong, AH., The rise of dermatology FOAMed in the pandemic landscape. Partyline. Issue 79, June 2022.
Willems, A., Chong, AH., Teledermatology: The way of the future? Partyline. Issue 78, March 2022.
Sun, Q., McMahon, D.E., Ugwu-Dike, P.O., Sun, Q., Tang, K., Zhang, H., Suchonwanit, P., Oh, C.C., Chong, A.H., Willems, A., Galván, C. et al., 2021. How COVID-19 Changed Dermatology Practice in One Year Around the World: Perspectives From 11 Countries. Dermatologic Clinics.
Ryan, C., Guenther, L., Foley, P., Weisman, J., Burge, R. T., Gallo, G., See, K., McKean‐Matthews, M., Bertram, C. C., & Merola, J. F. (2021). Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(4). https://doi.org/10.1111/jdv.17836
Reich, K., Gordon, K. B., Strober, B., Langley, R. G., Miller, M., Yang, Y. W., Shen, Y. K., You, Y., Zhu, Y., Foley, P., & Blauvelt, A. (2022). Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: Age, body weight, baseline psoriasis area and severity index, and Baseline Investigator’s global assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18474
Foley, P., Chong, A. H., Davenport, R., & Adamson, S. R. (2022, July 1). Scalp pruritus – scratching for answers. Medicine Today. Retrieved September 21, 2022, from https://medicinetoday.com.au/2022/july/feature-article/scalp-pruritus-scratching-answers
Thaçi, D., Strober, B., Gordon, K. B., Foley, P., Gooderham, M., Morita, A., Papp, K. A., Puig, L., Menter, M. A., Colombo, M. J., Elbez, Y., Kisa, R. M., Ye, J., Napoli, A. A., Wei, L., Banerjee, S., Merola, J. F., & Gottlieb, A. B. (2022). Deucravacitinib in moderate to severe psoriasis: Clinical and quality-of-life outcomes in a phase 2 trial. Dermatology and Therapy, 12(2), 495–510. https://doi.org/10.1007/s13555-021-00649-y
Foley, P., Tsai, T.-F., Rodins, K., Hamadah, I. R., Ammoury, A., Dayem, H. A., Abdallah, M., Crowe, S., Haas, S., Pournara, E., Jagiello, P., & Huang, Y.-H. (2022). Effectiveness and safety of secukinumab for psoriasis in a real-world clinical setting in the Asia-Pacific and Middle East regions: Results from the Realia Study. Dermatology and Therapy, 12(2), 511–527. https://doi.org/10.1007/s13555-021-00675-w
Foley, P., Manuelpillai, N., Dolianitis, C., Cains, G. D., Mate, E., Tronnberg, R., & Baker, C. (2022). Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice ( sustain study). Australasian Journal of Dermatology, 63(3), 303–311. https://doi.org/10.1111/ajd.13895
Murrell, D. F., Patsatsi, A., Stavropoulos, P., Zeeli, T., Kern, J. S., Sinclair, R., Neale, A., Arora, P., Sugerman, P. B., Shi, G., Werth, V. P., Caux, F., Joly, P., & Baum, S. (2022). Phase 2 believe study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 36(10). https://doi.org/10.1111/jdv.18318
Gretzmeier, C., Pin, D., Kern, J. S., Chen, M., Woodley, D. T., Bruckner-Tuderman, L., de Souza, M. P., & Nyström, A. (2022). Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology, 142(4). https://doi.org/10.1016/j.jid.2021.09.008
Simpson, K., Low, Z. M., Yap, T., Kern, J. S., & Scardamaglia, L. (2021). Ultralow‐dose rituximab in pemphigus: A single‐centre experience. British Journal of Dermatology, 186(3), 581–583. https://doi.org/10.1111/bjd.20819
Schauer, F., Mai, S., Hofmann, S. C., Mai, Y., Izumi, K., Kern, J. S., & Kiritsi, D. (2022). Autoreactivity to BP180 neoepitopes in patients with pemphigoid gestationis. JAMA Dermatology, 158(2), 212. https://doi.org/10.1001/jamadermatol.2021.5294
McClatchy, J., Yap, T., Koo, K., Kern, J. S., & Scardamaglia, L. (2021). De-escalation of anti-CD20 monoclonal antibody (rituximab) protocols in PEMPHIGUS VULGARIS – a systematic review. Expert Opinion on Biological Therapy, 21(12), 1591–1601. https://doi.org/10.1080/14712598.2021.1937118
Low, Z. M., Scardamaglia, L., Morgan, V., & Kern, J. S. (2021). Australian teledermatology experience during COVID‐19. Australasian Journal of Dermatology, 62(4). https://doi.org/10.1111/ajd.13681
Murrell, D. F., Patsatsi, A., Stavropoulos, P., Baum, S., Zeeli, T., Kern, J. S., Roussaki‐Schulze, A. V., Sinclair, R., Bassukas, I. D., Thomas, D., Neale, A., Arora, P., Caux, F., Werth, V. P., Gourlay, S. G., & Joly, P. (2021). Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: The phase II believe study*. British Journal of Dermatology, 185(4), 745–755. https://doi.org/10.1111/bjd.20431
Simpson, K., Low, Z. M., Howard, A., & Kern, J. S. (2021). Successful management of treatment resistant nail psoriasis with tildrakizumab. Australasian Journal of Dermatology, 62(3), 390–393. https://doi.org/10.1111/ajd.13642
Simpson, K., Scardamaglia, L., Kok, Y., Vu, M., Kidd, D., Yap, T., Tran, Y., & Kern, J. S. (2021). Comparison of the EUROIMMUN dermatology profile Elisa to the novel Biochip Mosaic 7 for the diagnosis of immunobullous skin disease. Australasian Journal of Dermatology, 62(3), 314–322. https://doi.org/10.1111/ajd.13611
Williams, C., Hunt, J., Kern, J. S., & Dunn, R. (2021). A CASEMIX study of patients seen within an urban Aboriginal Health Service Dermatology Clinic over a five‐year period. Australasian Journal of Dermatology, 62(3), 331–335. https://doi.org/10.1111/ajd.13630
Dear, K., Gan, D., Stavrakoglou, A., Nixon, R., & Ronaldson, C. (2022). Hyperkeratotic flexural erythema (more commonly known as granular parakeratosis) with use of laundry rinses containing benzalkonium chloride – a case series. Clinical and Experimental Dermatology. https://doi.org/10.1111/ced.15358
Punchewa N, Palmer A, Nixon R. Allergic contact dermatitis to Compositae: an Australian case series. Contact Dermatitis 2022; DOI: 10.1111/cod.14162
Mizutani H, Felmingham C, Palmer A, Tate B, Tam MM, Nixon R. Allergic contact cheilitis in Melbourne, Australia. Contact Dermatitis 2022; DOI: 10.1111/cod.14165.
Patel, K., Nixon, R. Irritant contact dermatitis — a review. Curr Derm Rep 2022; 11, 41–51.
Patel K, Nixon R. Mask exemptions for facial skin diseases – are they warranted? Med J Aust 2022; 216 (9): DOI: 10.5694/mja2.51513.
Patel K, Nixon R. Allergic contact dermatitis to black rubber in firefighters’ masks: A case series. Contact Dermatitis 2022; 86; 136-7.
Nguyen J, Nixon R, Lee A. Allergic contact dermatitis caused by polyurethane components in bulletproof glass manufacturing. Contact Dermatitis; 86(4):325-326.
Agner T et al. Guidelines for diagnosis, prevention and treatment of hand eczema
Contact Dermatitis; 86: 357-378.
Chiu FPC, Nixon R, Lee A, Boyce A. “High-vis” dermatitis. Contact Dermatitis DOI: 10.1111/cod.14033
Patel K, Shimmin A, Nixon RL. Testing to Dermabond pre-operatively to reduce the likelihood of allergic skin reactions. ANZ J Surg 2021;91(11):2548-2549.
Ng KL, Grills C, Tam MM, Nixon R. A solution using Stomadhesive® wafers for allergic contact dermatitis caused by isobornyl acrylate in glucose monitoring sensors. Australas J Dermatol 63(1):e56-e59.
Scheinman, P.L., Vocanson, M., Thyssen, J.P. Vocanson M, Thyssen JP, Johansen JD, Nixon RL, Dear K, Botto, Morort, Goldminx A. Contact Dermatitis. Nat Rev Dis Primers 7, 38 (2021). https://doi.org/10.1038/s41572-021-00271-4
Ng KL, Nixon RL, Grills C, Tam MM. Solution using Stomahesive® wafers for allergic contact dermatitis caused by isobornyl acrylate in glucose monitoring sensors. Australas J Dermatol 2022 Feb;63(1):e56-e59.
Nixon, R., & Patel, K. (2021, July). Irritant contact dermatitis. DermNet. https://dermnetnz.org/topics/irritant-contact-dermatitis
Nixon, R., & Ronaldson, C. (2021, August). House dust mite. DermNet. Retrieved September 26, 2022, from https://dermnetnz.org/topics/house-dust-mite
Nixon, R., & Danielle, M. G. (2022). Australian Standards for Protective Gloves. In R. N. Phalen & H. I. Maibach (Eds.), Protective gloves for occupational use. CRC Press.
Mizutani H, Nguyen J, Tam MM, Tate B, Cahill J, Nixon R. Patch test reactivity to iodopropynyl butylcarbamate between 2011 and 2018 in Melbourne, Australia. Contact Dermatitis 2021 Nov;85(5):604-606.
Mactaggart E, Orchard D, Tam MM. Baby wipes and nappy rash – what is the relationship? A review. Australas J Dermatol 2021 Nov;62(4):470-477
Ting S, Tam M, Kelly R. Scarring in pyoderma gangrenosum. Australas J Dermatol 2021 Nov;62(4):523-525
Mactaggart E, Orchard D, Tam MM. Baby wipes and nappy rash – what is the relationship? A review. Australas J Dermatol 2021 Nov;62(4):470-477
Ting S, Tam M, Kelly R. Scarring in pyoderma gangrenosum. Australas J Dermatol 2021 Nov;62(4):523-525
Mahar PD, Panaccio DCA, Dean JM, Farmer CC, Pang CP, Kevat DAS. Managing negative online reviews: considerations for doctors. Australian Journal of General Practice 2022;(58)2:568-570
Mahar PD, Zubrinich C, Manuelpillai N, Foley P. Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma. Australasian Journal of Dermatology 2021; 62(4): 506-508
Kevat DAS, Farmer CC, Mahar PD, Panaccio DCA. Legal and ethical pitfalls in mandatory vaccination of residential aged care facility workers. MJA Insight+ 2021; 25
Kevat DAS, Panaccio DCA, Pang SC, Dean JM, Farmer CF, Mahar PD. Medicolegal considerations of mandatory COVID-19 vaccination for high-risk workers. Medical Journal of Australia 2021; 215(1):45(5):622-626
Punchihewa N, Odhavji S, Upjohn E, Bekhor P. Immunostained Frozen Sections Vs Traditional Permanent Paraffin Sections for Lentigo Maligna Treated With Mohs Micrographic Surgery. Dermatol Surg. 2022 Jan 1;48(1):43-46. doi: 10.1097/DSS.0000000000003280. PMID: 34772830.
